BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

BTIG analyst Mark Massaro announced an increased price target for IDEXX Laboratories (NASDAQ:IDXX), raising it from $500 to $530, while maintaining a Buy rating on the stock. The revision follows ...

BTIG analyst Clark Lampen raised the firm’s price target on DraftKings (DKNG) to $59 from $55 and keeps a Buy rating on the shares as part of a ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Analysts at BTIG moved to the sidelines on online dating apps company Match Group (NASDAQ:MTCH) and lowered its investment rating to "Neutral" from "Buy" on Tuesday. The research firm said its ...

The Company has recently announced execution of an agreement for $27 million in funding for HOPE <a target=_blank href= ...